Egetis Therapeutics AB (publ) (EGTX): key financial figures for fiscal year 2025 (in SEK), standardized from XBRL/iXBRL filings by Hub-Equity:

Revenue (FY2025): kr 62.4M
Net Income/Loss (FY2025): -kr 342.5M
Total Assets (FY2025): kr 639.1M
Total Equity (FY2025): kr 338.7M
Cash Flows from Operating Activities (FY2025): -kr 267.0M

Source: Egetis Therapeutics AB (publ) annual_report filing (FY2025). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.

Egetis Therapeutics AB (publ) (EGTX): key financial figures for fiscal year 2025 (in SEK), standardized from XBRL/iXBRL filings by Hub-Equity:

Revenue (FY2025): kr 62.4M
Net Income/Loss (FY2025): -kr 342.5M
Total Assets (FY2025): kr 639.1M
Total Equity (FY2025): kr 338.7M
Cash Flows from Operating Activities (FY2025): -kr 267.0M

Source: Egetis Therapeutics AB (publ) annual_report filing (FY2025). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.